Area of research
Molecular Biology · Physiology
Research interest
Research interests include Amyloidosis: Diagnosis, Treatment, Outcomes, Pain Mechanisms and Treatments, Parathyroid Disorders and Treatments, and Skin and Cellular Biology Research.
Five-Year Results With Patisiran for Hereditary Transthyretin Amyloidosis With Polyneuropathy
Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the <scp>United States</scp>: <scp>Recommendations</scp> from a panel of experts
Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study.
Joint Hypermobility, Autonomic Dysfunction, Gastrointestinal Dysfunction, and Autoimmune Markers: Clinical Associations and Response to Intravenous Immunoglobulin Therapy.
A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata.
Symptoms of Hereditary Transthyretin Amyloidosis: The Patient and Physician Perspective.
Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial.
Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy
Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay
Phenotypes Associated With the Val122Ile, Leu58His, and Late-Onset Val30Met Variants in Patients With Hereditary Transthyretin Amyloidosis.
Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial
Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update
Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update
Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis
Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey
Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression
Research design considerations for chronic pain prevention clinical trials: IMMPACT recommendations
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study
Early data on long‐term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2‐year update from the open‐label extension of the NEURO‐TTR trial
Idiopathic distal sensory polyneuropathy: ACTTION diagnostic criteria.
A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis
Development of measures of polyneuropathy impairment in hATTR amyloidosis: From NIS to mNIS + 7
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial
The Potential Role of Sensory Testing, Skin Biopsy, and Functional Brain Imaging as Biomarkers in Chronic Pain Clinical Trials: IMMPACT Considerations
Assessing mNIS+7<sub>Ionis</sub> and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial
Na<sub>V</sub>channel variants in patients with painful and nonpainful peripheral neuropathy
Peripheral neuropathic changes in pachyonychia congenita